Veliparib (ABT-888)

Catalog No.S1004 Synonyms: NSC 737664

For research use only.

Veliparib (ABT-888, NSC 737664) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Veliparib increases autophagy and apoptosis. Phase 3.

Veliparib (ABT-888) Chemical Structure

CAS No. 912444-00-9

Selleck's Veliparib (ABT-888) has been cited by 205 publications

Purity & Quality Control

Choose Selective PARP Inhibitors

Other PARP Products

Biological Activity

Description Veliparib (ABT-888, NSC 737664) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Veliparib increases autophagy and apoptosis. Phase 3.
Features Increases the efficacy of common cancer therapies such as radiation and alkylating agents.
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
2.9 nM(Ki) 5.2 nM(Ki)
In vitro

ABT-888 is inactive to SIRT2 (>5 μM). [1] ABT-888 inhibits the PARP activity with EC50 of 2 nM in C41 cells. [2] ABT-888 could decrease the PAR levels in both irradiated and nonirradiated H460 cells. ABT-888 also reduces clonogenic survival and inhibits DNA repair by PARP-1 inhibition in H460 cells. ABT-888 increases apoptosis and autophagy in H460 cells when combination with radiation. [3] ABT-888 also inhibits PARP activity in H1299, DU145 and 22RV1 cells and the inhibition is independent of p53 function. ABT-888 (10 μM) suppresses the surviving fraction (SF) by 43% in the clonogenic H1299 cells. ABT-888 shows effective radiosensitivity in oxic H1299 cells. Furthermore, ABT-888 could attenuate the SF of hypoxic-irradiated cells including H1299, DU145 and 22RV1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
C41 MYPLbY5ie2ViQYPzZZk> NUmxdno4OzBibXnu MnW1TY5pcWKrdHnvckBw\iCSQWLQNUB4cXSqIFXDOVAhd2ZiMD6wNFIh|ryP M4rXNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OEi4O|YxLz5zOUi4PFc3ODxxYU6=
Jurkat MoX3T4lv[XOnIFHzd4F6 MUO5OkBp MkjlSG1UVw>? M1PjT2lvcGmkaYTpc44hd2ZiUFHSVFEh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIH;mJINmdGxidnnhZoltcXS7IIfpeIghTUN3MDDv[kA{KM7:TR?= M2m2WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OEWwNVk6Lz5{M{i1NFE6QTxxYU6=
Capan1 NUX6bWxlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmOyO|IhcA>? NEHTdnJFVVOR MWnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IFLSR2EzKGenbnWgcZV1[XSnZDDoeY1idiCFYYDhclEh[2WubIOge4l1cCCLQ{WwJI9nKDN7Lkeg{txO NFGwT489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO5PFM5Oyd-MkSzPVg{QDN:L3G+
DT40 NHjZVndEgXSxdH;4bYMhSXO|YYm= M{nFeVczKGh? NYPDW5psTE2VTx?= MVjDfZRwfG:6aXPpeJkh[WejaX7zeEBkcGmla3XuJGJTS0F{LXTl[olkcWWwdDDEWFQxKGOnbHzz MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl{MkW4O{c,OjR7MkK1PFc9N2F-
ML-1 NGfkUVVCeG:ydH;0bYMhSXO|YYm= NWO4N4pQOi53IN88US=> M{O1dlI1KGh? MmfzSG1UVw>? NFHieoxUgW6ncnfpd5Rq[2GubImg[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXNiaX6gUWwuOSClZXzsdy=> NHPRc5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi5OVE{PSd-MkS4PVUyOzV:L3G+
HCT-116 MUXLbY5ie2ViQYPzZZk> NYX1emY4OC53IN88US=> NYX5OlVIOjRiaB?= NHvJZm5RSVKSIHHjeIl3cXS7IHTlZ5Jm[XOncx?= NXfsU29uRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOVQzOTNpPkKzNFU1OjF|PD;hQi=>
UM-SCC1 NVXjenBYS3m2b4TvfIlkKEG|c3H5 MVWxNEDPxE1? NYfGVGROOjRiaB?= MYXS[YR2[2W|IITo[UBk\WyuII\pZYJqdGm2eR?= NIPob4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUmxNlYzOCd-MkG5NVI3OjB:L3G+
FaDu M{XGb2N6fG:2b4jpZ{BCe3OjeR?= NFXldoUyOCEQvF2= M3HDZ|I1KGh? MmPCVoVlfWOnczD0bIUh[2WubDD2bYFjcWyrdIm= MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTlzMk[yNEc,OjF7MUK2NlA9N2F-
PC-3 NFfkU4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXVWYIyOCEQvF2= MlrrTY5lfWOnczDhJJNq\26rZnnjZY51KGmwaHnibZRqd25iaX6gZ49td267IH\vdo1ifGmxbtMg NVq0d2x7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG1O|E6OTJpPkKxOVcyQTF{PD;hQi=>
C41 NIfYOnNHfW6ldHnvckBie3OjeR?= MlnsTY5pcWKrdHnvckBw\iCSQWLQNUBqdiCqdX3hckBEPDFiY3XscJMtKEWFNUCgQUAxNjByMjFOwG0v NWO2VFRFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxOFM2PjlpPkG5NVQ{PTZ7PD;hQi=>
LoVo NIPFS3lHfW6ldHnvckBie3OjeR?= MlS3N|AhdWmwcx?= MnfZTY5pcWKrdHnvckBw\iCSQWLQJIlvKGi3bXHuJGxwXm9iY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBxd2y7KFHEVEkuemmkb4PlJJBwdHmvZYLpfoF1cW:wIH\vdkA{OCCvaX7zJIJ6KG[udX;y[ZNk\W6lZTDhd5NigSxiRVO1NEA:KDBwMEC1PVQh|ryPLh?= M3vyelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyO|E4Lz5{Nk[1NlcyPzxxYU6=
LoVo MWfGeY5kfGmxbjDhd5NigQ>? NFzh[2k{OCCvaX7z NVO0cWVqUW6qaXLpeIlwdiCxZjDQRXJRKGmwIHj1cYFvKEyxVn:gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCyb3z5LGFFWClvcnnic5NmKHCxbInt[ZJqgmG2aX;uJIZweiB|MDDtbY5{KGK7IH\seY9z\XOlZX7j[UBie3OjeTygSWM2OCB;IECuNFA2QTRizszNMi=> NETXVJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1NlcyPyd-Mk[2OVI4OTd:L3G+
LoVo NWO2SmliTnWwY4Tpc44h[XO|YYm= NXvF[YtCOzBibXnudy=> MYHJcohq[mm2aX;uJI9nKFCDUmCgbY4hcHWvYX6gUI9XdyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJBwdHlqQVTQLU1zcWKxc3WgdI9tgW2ncnn6ZZRqd25iZn;yJFMxKG2rboOgZpkh\my3b4Lld4NmdmOnIHHzd4F6NCCHQ{WwJF0hOC5yMEW5OEDPxE1w MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3MkexO{c,OjZ4NUK3NVc9N2F-
VC8 NFHmS49EgXSxdH;4bYNqfHliYYPzZZk> MUCzJIRigXN? M2XtU2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KEOqaX7ld4UhcGGvc4TldkBXSzhiY3XscJMhcGG{Yn;ybY5oKEKUQ1GyJIRm\mmlaXXueEBi\nSncjCzJIRigXNiYomgR2NMQCCjc4PhfUwhS0N3MDC9JFIvOzR2IN88UU4> M3fZXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7M{O1NlA2Lz5{OUOzOVIxPTxxYU6=
LoVo MX7DfZRwfG:6aXPpeJkh[XO|YYm= NX[xW3hkOC52IIXN M{C5UFUh\GG7cx?= MULQc5RmdnSrYYTpc44hd2ZidHXtc5pwdG:vaXTlMYlv\HWlZXSgZ5l1d3SxeHnjbZR6KGmwIHj1cYFvKEyxVn:gZ4VtdHNiYYPz[ZN{\WRiYYOgeIVud3qxbH;tbYRmKEeLNUCgZZQhOC52IIXNJIFnfGW{IEWg[IF6eyCkeTDD[YxtfGm2ZYKtS4xwKGG|c3H5MEBIUTVyIE2gOk4zODNizszNMi=> M4SxelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyO|E4Lz5{Nk[1NlcyPzxxYU6=
A673 NVSz[pF6eUiWUzDhd5NigQ>? NXH5TpFQeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFG2O|Mh[2WubIO= MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Saos-2 MX;xTHRUKGG|c3H5 NXLsdpZleUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=> M1jLRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643 NIDSRpZyUFSVIHHzd4F6 Mn7DdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?= NXvZUXJ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH M3THTJFJXFNiYYPzZZk> MX3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBQenSqb3fvcoFtKDOGII\pZYJqdGm2eTDzZ5Jm\W5iZn;yJHNMNU5vU1igZ4VtdHN? MmfiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC MV3xTHRUKGG|c3H5 NGfaXGVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=> M3nGVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
TC32 MWnxTHRUKGG|c3H5 NWXkNXN7eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXEN|MjDj[Yxtew>? MmrOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2 MUXxTHRUKGG|c3H5 MX;xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBQenSqb3fvcoFtKDOGII\pZYJqdGm2eTDzZ5Jm\W5iZn;yJHNLNUeETUKgZ4VtdHN? NEjMUJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
EoL-1-cell NIDFO|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HMZmlEPTB;MT6wO|k5KM7:TR?= MmnoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
NCI-SNU-5 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLITWM2OD1|LkGyPFQyKM7:TR?= M2\iZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
BV-173 MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrVTWM2OD13LkS1OFA6KM7:TR?= M3HucVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
HCC1806 MoOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTVwN{WxO|Mh|ryP NV3LWXdwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?
COLO-680 Ml7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTZwMkG0NFYh|ryP NGTP[XU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK|5USU6JRWK8M4E,
HCC2218 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jzT2lEPTB;Nz63PVcxPCEQvF2= Mo\BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
SK-MEL-24 NV3TWJoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTdwOEG5NlQh|ryP MlvIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
NCI-H720 NXr1[IZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHNZmFKSzVyPUiuOFM3ODNizszN NGfVdWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK|5USU6JRWK8M4E,
KASUMI-1 Ml7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfwRnVKSzVyPUiuPFkzPjZizszN NXu3W|N4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?
HAL-01 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zxdGlEPTB;OT64PFYzKM7:TR?= NYX6c2RRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?
CAL-33 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHmWI1zUUN3ME2xNE41OzRizszN MnO5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
SK-MEL-1 NFrFOG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGSwUoNKSzVyPUGyMlQ3PjNizszN NH;Zeng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK|5USU6JRWK8M4E,
Ramos-2G6-4C10 NV3FNos4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTRUVlDUUN3ME2xNk41PzV{IN88US=> MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
KY821 NYTXdnVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjrNVRQUUN3ME2xNk41QDVizszN M4rVTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
HEC-1 NXXOeHF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\hTWM2OD1zMj65NVk3KM7:TR?= M{jtRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
SK-NEP-1 Ml7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3MbG9KSzVyPUGzMlE3PiEQvF2= MoXMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
MN-60 MorhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWP6cHlsUUN3ME2xN{42Ozh7IN88US=> MmjNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
DU-145 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7XUmVNUUN3ME2xN{46ODV|IN88US=> MkGzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
EW-3 M1fLTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPuSFg4UUN3ME2xOE42PTZ3IN88US=> M4e4O|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
OS-RC-2 NX3zXlZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTF3Lkm1PFkh|ryP M2DyU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
RPMI-8226 NFz4W5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfKPXFUUUN3ME2xOk4zODR{IN88US=> MkPnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
ChaGo-K-1 NHnTXINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzZOWQyUUN3ME2xOk42OzJ3IN88US=> MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
DEL NWHEc3RmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXrTWM2OD1zNj62O|E4KM7:TR?= MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
GP5d NVLVbWQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFiwUWxKSzVyPUG3MlA2OyEQvF2= M4\XPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
COLO-668 NUe4XopET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XvV2lEPTB;MUeuOlI6PCEQvF2= MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
H9 M4C0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlGxTWM2OD1zOD6yPFM{KM7:TR?= NXnl[ZlyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?
NKM-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLjboVSUUN3ME2xPE42OTF7IN88US=> MonlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
KYSE-150 NFfTWYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;ocFFKSzVyPUG4Mlk6QDZizszN M37PPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
Daoy M3\Pd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmi3TWM2OD1zOT61OlQ6KM7:TR?= NV3ZW|ZxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?
ECC10 Ml2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrHTYNLUUN3ME2yNE44PDV3IN88US=> M1HD[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
A388 M4HQZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTJzLkmwPVEh|ryP MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
MHH-NB-11 NVPiSGx{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrYZ|JtUUN3ME2yN{4yOzZ|IN88US=> M1fST|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
HCC1937 M3S4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTJ2Lke0OkDPxE1? MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
TGBC11TKB NXPxcYJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXEfWVYUUN3ME2yOU43QDZ|IN88US=> MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
CTV-1 NHHTOlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTJ3Lki5Olkh|ryP MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
NCI-H2029 MmDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPSTWM2OD1{Nj60NlM5KM7:TR?= Ml7rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
HLE MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvNe|RHUUN3ME2yO{4xPTRizszN M4nXVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
NCI-H1693 MkXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTJ5LkK4PVgh|ryP Mmi4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
HCC70 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPBT5dKSzVyPUK3MlczPDZizszN NXXxOGlORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?
BEN M3HTW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7xO4c3UUN3ME2yO{46PTZ4IN88US=> NXzPZoN6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?
LB771 M4XRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTJ6LkizO|Mh|ryP M4TlWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
697 M1\3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3xd5VKSzVyPUK5MlAzOzVizszN MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
LU-139 NUjTV|BuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;Q[5VKSzVyPUK5MlM4PDhizszN NF:1UIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK|5USU6JRWK8M4E,
EW-13 M{W4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFr6b3NKSzVyPUK5MlM5OTRizszN M1\SW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
MOLT-13 NELyWHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7Td|dKUUN3ME2yPU4{QDF2IN88US=> NIXI[Jo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK|5USU6JRWK8M4E,
L-363 NF3JS|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHaTWM2OD1{OT60O|k5KM7:TR?= NFL3eGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK|5USU6JRWK8M4E,
EM-2 M3LCcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfZeHRPUUN3ME2yPU41QTBzIN88US=> NXHYeVRsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?
RS4-11 M3zsZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\oWmlEPTB;M{CuOFI1OSEQvF2= MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
A2780 M{Ptc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIe5ZVRKSzVyPUOwMlc1PTdizszN M4q1W|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
KU812 M4HXb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\VVGs4UUN3ME2zNk4{PjR{IN88US=> NHuySW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK|5USU6JRWK8M4E,
COLO-684 M3Lse2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXSUWpwUUN3ME2zN{4{PTl7IN88US=> NID0fYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK|5USU6JRWK8M4E,
MFE-280 MljOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjM[G9KSzVyPUOzMlM5QDlizszN NXfLSndGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?
KG-1 MoXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlr3TWM2OD1|Mz62NFAyKM7:TR?= NWDHTIJkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?
JVM-3 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTHOHdKSzVyPUO1MlU5PjhizszN M2\wflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
MV-4-11 NYfvcXpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLwTWtKSzVyPUO1Mlg1QTlizszN MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
LAMA-84 NV3lNGUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTN4LkezOFUh|ryP MlvPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
MOLT-16 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\Qd2VKSzVyPUO2Mlk2OiEQvF2= M{HZOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
H4 Mnv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHhNpNKSzVyPUO3MlU3PyEQvF2= NHX3O|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK|5USU6JRWK8M4E,
T47D M2Hnemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3v2O2lEPTB;M{euO|AyQCEQvF2= M3voWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
CAL-54 NWLXV2U3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIj0cYRKSzVyPUO3Mlk3PiEQvF2= Mn7wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
SW982 M2jhdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHmS5VwUUN3ME2zPE4xQTl6IN88US=> NEGzT4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK|5USU6JRWK8M4E,
IGROV-1 NInxNJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYiwN|hFUUN3ME2zPU4{OzB2IN88US=> MkCyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
NB14 M{PjfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHwRnRKSzVyPUSwMlcxOzFizszN Mn3KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
HCC1187 NITReo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\ERmlEPTB;NEGuNlc4OSEQvF2= MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
SBC-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3KyOmlEPTB;NEGuN|A3OyEQvF2= M4PJTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
KARPAS-45 MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnGzTWM2OD12MT60PFE5KM7:TR?= MnvrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
MOLT-4 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zNV2lEPTB;NEKuNlU{QCEQvF2= MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
JVM-2 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTR{LkmyNFch|ryP MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
A4-Fuk NVHkfo9RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGe1[5NKSzVyPUSzMlU3QTFizszN NV3zOm9pRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?
MDA-MB-361 NELQdW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;xZmlEPTB;NEOuPFQyPCEQvF2= NEnJZ409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK|5USU6JRWK8M4E,
BALL-1 MlPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXq1NJJlUUN3ME20N{46PTN{IN88US=> MoO1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
T98G NV;wSJpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTR2Lki1NVch|ryP MnW0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
Mo-T NVzjfppoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTR3Lk[zPFkh|ryP M2PEe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
MHH-PREB-1 M3yyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;ZcmlEPTB;NEWuO|U5PSEQvF2= NEi0R|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK|5USU6JRWK8M4E,
ALL-PO MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvuVFFKSzVyPUS3MlM4QTFizszN MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
NCI-H510A NXLMd|VDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;tcWxKSzVyPUS3MlkxOzRizszN NGTxVmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK|5USU6JRWK8M4E,
ML-2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHG3dW9KSzVyPUS5Mlc5PTZizszN MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
Assay
Methods Test Index PMID
Western blot p-STAT3 / STAT3 / p-AKT(S473) / p-AKT(T308) / p-ERK / p-p38 22678161
Immunofluorescence HuR ; BRCA1 28687616 21917757
Growth inhibition assay Cell viability (TNBC cell lines) ; Cell viability (melanoma cells) 27880910 29956724
In vivo The oral bioavailability of ABT-888 is 56%-92% in mice, Sprague-Dawley rats, beagle dogs, and cynomolgus monkeys after oral administration. [1] ABT-888 (25 mg/kg i.p.) could improve tumor growth delay in a NCI-H460 xenograft model with well tolerated. Combination with radiation, ABT-888 decreases the tumor vessel formation. [3] ABT-888 reduces intratumor PAR levels by more than 95% at a dose of 3 and 12.5 mg/kg in A375 and Colo829 xenograft models and the suppression could be maintained over time. [4]

Protocol (from reference)

Animal Research:

[1]

  • Animal Models: NCI-H460, H460, B16F10 and 9L xenografts in C57BL/6 mice
  • Dosages: ~25 mg/kg
  • Administration: Orally administered

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
0.5% methylcellulose+0.2% Tween 80
For best results, use promptly after mixing.

5 mg/mL

Chemical Information

Molecular Weight 244.29
Formula

C13H16N4O

CAS No. 912444-00-9
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1(CCCN1)C2=NC3=C(C=CC=C3N2)C(=O)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03044795 Withdrawn Drug: Veliparib Cancer University Medical Center Groningen|AbbVie|Dutch Cancer Society November 2019 Phase 2
NCT02723864 Completed Drug: Veliparib + VX-970 + Cisplatin Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 9 2017 Phase 1
NCT02483104 Completed Drug: veliparib|Drug: carboplatin|Drug: paclitaxel Ovarian Cancer AbbVie July 2015 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Veliparib (ABT-888) | Veliparib (ABT-888) supplier | purchase Veliparib (ABT-888) | Veliparib (ABT-888) cost | Veliparib (ABT-888) manufacturer | order Veliparib (ABT-888) | Veliparib (ABT-888) distributor